U.K.-based CDMO Upperton Pharma Solutions expanded its production footprint with the completion of a new £7 million ($8.1 million) sterile manufacturing facility at its Nottingham campus.
The 7,000-square-foot facility adds to the company’s pre-existing 50,000 square feet of manufacturing space, the company said in a Jan. 29 press release. The new plant will support the production of aseptic and sterilized small-volume liquids and powders for parenteral, nasal and pulmonary delivery.
The new site is capable of handling formulation development, clinical manufacturing and analytical testing, with batch sizes of up to 2,000 vials, pre-filled syringes and pre-filled cartridges for liquid formulations and pre-sterilized powders, the company said.
“The combined experience of our leadership team in sterile facility builds and subsequent operations ensures that we are ideally placed as a CDMO partner of choice for small to mid-sized biotech and pharma looking to get into the clinic quickly with fast access to sterile manufacturing services,” Nikki Whitfield, Upperton’s chief executive, said in the release.
Founded in 1999, Upperton completed its prior Nottingham facility buildout in July of 2023 after pumping £15 million ($19.6 million at the time) into the project. At the time, the company touted powder blending capacity of up to 250 kilograms per batch, capsule filling capacity at up to 40,000 capsules an hour and other services.